

EU GastScreen Pilot study

European-Taiwan Cancer Screening Conference, 2026

Mārcis Leja
Institute of Clinical and
Preventive Medicine
University of Latvia

Riga
October 7, 2026



Co-funded by
the European Union

EU Council Recommendation, 2022



	BREAST CANCER suggesting a lower age limit of 45 and a higher age limit of 74 (standard 50 – 69), plus MRI scans when medically appropriate		HPV testing for women aged 30 to 65, every 5 years or more, to detect CERVICAL CANCER, taking account of HPV vaccination status		Triage testing for COLORECTAL CANCER in people aged 50 – 74 through faecal immunochemical testing (FIT) to determine follow-up via endoscopy/colonoscopy
	LUNG CANCER testing for individuals at high risk (i.e. smokers), incl. prevention approaches		Prostate specific antigen testing for PROSTATE CANCER in men, plus MRI scans for follow-up		In places with high GASTRIC CANCER incidence and death rates, screening for Helicobacter pylori and surveillance of precancerous stomach lesions

Gastric cancer

Screening for *Helicobacter pylori* should be considered in those countries or regions inside countries with high gastric cancer incidence and death rates, according to thresholds to be defined in European guidelines with quality assurance. Screening should also address strategies for identification and surveillance of patients with **precancerous stomach lesions** unrelated to *Helicobacter pylori* infections. Considering the evidence for screening and the need for a stepwise approach, countries should begin to test the feasibility of this programme, including by using implementation studies.



Breast cancer guidelines and
quality assurance



Cervical cancer guidelines and
quality assurance



Colorectal cancer guidelines and
quality assurance



Gastric cancer guidelines and
quality assurance




Lung cancer guidelines and
quality assurance



Prostate cancer guidelines and
quality assurance

EUROHELICAN (& TOGAS)



- General population
- 30-34 years
- 2000 subjects tested

Tepes et al. Helicobacter. 2026

Which is the most appropriate age for *screen and treat*




Early adulthood

- Higher effectiveness – no precancerous conditions
- Potential combination to health check-ups (if available)
- Avoiding transmission to offspring



Middle age

- Better participation
- Potential combination to other screenings
- Potentially higher cost-effectiveness




Screening for *Helicobacter pylori* to Prevent Gastric Cancer

A Pragmatic Randomized Clinical Trial

Yi-Chia Lee, MD, PhD; Tsung-Hsien Chiang, MD, PhD; Han-Mo Chiu, MD, PhD; Wei-Wen Su, MD; Kun-Ching Chou, MD; Sam Li-Sheng Chen, PhD; Amy Ming-Fang Yen, PhD; Jean Ching-Yuan Fann, PhD; Sherry Yueh-Hsia Chiu, PhD; Shu-Lin Chuang, PhD; Yi-Ru Chen, MSc; Shih-Dian Chen, MD; Tsung-Hui Hu, MD, PhD; Yi-Jen Fang, MD, PhD; Ming-Shiang Wu, MD, PhD; Tony Hsiu-Hsi Chen, PhD; Yen-Po Yeh, MD, PhD; for the Collaborators of Taiwan Community-based Integrated Screening Group

2024



***H.pylori* antigen in combination to FIT screening**

EU GastScreen pilot study



Co-funded by
the European Union

Random selection of individuals aged ≥ 50 years or earliest recommended CRC screening age

Invitation, feedback collection, reminder, test bottles delivery

Dual simultaneous testing, results communication

FIT positive

SAT positive

SAT and FIT negative

Phone interview: explanation of results,
questionnaire, registration for follow-up procedure

Feedback collection and
end of screening follow-up

Consultation, prescription of
medication and colonoscopy/
clinical management
according to local practice

Consultation for informed decision-making on
eradication of *H. pylori* and/or upper endoscopy

H. pylori eradication, testing for success of eradication

¹³C UBT positive

¹³C UBT negative

2nd line treatment and
testing for success

Feedback collection and end of screening follow-up

Target numbers (tests performed)




Country	Minimal target	Optimal target
Estonia	600	1000
Italy Bologna	500	1000
Italy- Emilia Romagna	500	1000
Latvia	1000	1500
Portugal	500	1000
Lithuania	1000	1000
TOTAL:	4100	6500

Challenges

- Mode of delivery (sampling bottles, sample)
- Stability of the sample in sampling bottle
- Accuracy of the test
- Acceptance of the eradication therapy
- Choice and availability of medication for eradication







Current status

- Ethics approval
 - Received in Latvia
 - Received in Portugal
 - Submitted in Italy
 - In process in Estonia and Lithuania
- ClinicalTrials.gov application submitted
- eCRF developed
- Multi-language data capture system in place

Developed projects

+ New project



Recommended templates

Show all X

SURVEY

Edinburgh Postnatal Depression Scale (EPDS)
EN, LV

SURVEY

Charleston Psychiatric Outpatient Satisfaction Scale (15-item)
EN, LV, RU

SURVEY

Default granularity options for consent
EN

ACTIVITY

Multiple Sclerosis: Support Societies and Information Resources
EN, LV

SURVEY

Patient Health Information Resources
EN, LV, RU

NUMBER OF PROJECTS: 2



Feedback on testing the "EUGastScreen" study

Edit



This project contains a feedback survey that collects comments from the focus group participants about their experiences trying out the EUGastScreen study participant path.

View activities >

Submissions 4 >

EUCanScreen - European implementation study on simultaneous screening for gastric and colorectal cancers

Edit



We invite you to participate in a pilot study that will help develop early detection and prevention options for stomach and bowel cancer.

View activities >

Submissions 39 >

Participants 14 >

Accessibility

English

L



Potential sister-studies

- New Zealand
- US
- Latin America
- Azerbaijan (collaborative grant application with Japan)

Acknowledgements



The team in Latvia

- Kateryna Priadko
- Yelena Tarasenko
- Paula Naļivaiko
- Maksims Jakovenko
- Daiga Šantare
- Aiga Rūdule

Longenesis

- Dārta Zaķe
- Ilva Kononova

GASTRO Centrs

- Danute Ražuka-Ebela
- Dace Dosone

Centrālā laboratory

- Edvīns Kazušs

International team

- Giuseppe Feliciangeli
- Silvia Taffetani
- Maurizio Zagari
- Tiziana Sanna
- Mário Dinis-Ribeiro
- Fernando Tavares
- Kaire Inos
- Thomas Zimmer
- Audrius Dulskas

External Advisory Committee

- Constanza Camargo
- Yi-Chia Lee
- Iris Lansdorp-Vogelaar
- Mangesh Thorat
- Jin Young Park



Thank you!

Contact us: screening@lu.lv



Co-funded by
the European Union

Disclaimer

Co-funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or HADEA. Neither the European Union nor the granting authority can be held responsible for them.